Heat-stable spore probiotic for targeted fat loss in companion animals

Overview

This technology is a patented probiotic strain, Clostridium cochlearium CC2316, developed for obesity and diabetes management. Unlike conventional carbohydrate-dependent probiotics, CC2316 metabolizes the amino acids glutamine and glutamate via the methylaspartate pathway to generate the short-chain fatty acids (SCFAs) acetate and butyrate. This amino-acid-driven metabolism enables the strain to function effectively in the nutrient environment of the distal colon, where traditional fiber-dependent microbes have limited activity.

In three independent diet-induced obesity mouse studies, CC2316 consistently demonstrated robust metabolic efficacy: a 22–28% reduction in body weight gain, selective reduction of fat mass without impacting lean mass, and significantly improved insulin sensitivity. The strain acts as a transient metabolic catalyst, delivering high-amplitude SCFA pulses without establishing long-term gut colonization, minimizing ecological disruption. Through acetate-supported cross-feeding, it remodels the endogenous gut microbial community to enrich native butyrate-producing bacteria, offering a biologically sustainable approach to metabolic health.

The technology is protected by US patent application 18/206,288 and is being developed as a supplement for companion animals (canine and feline), with potential applications in human metabolic health.

Technical specifications

Key features:

• Patented, human-derived, non-toxigenic, antibiotic-susceptible Clostridium cochlearium strain (CC2316)
• Produces acetate and butyrate from glutamine and glutamate fermentation, independent of dietary fiber
• Heat-stable spore formulation enables robust delivery and viability
• Selective fat mass reduction with preserved lean mass in preclinical models
• 22–28% reduction in body weight gain and improved insulin sensitivity in diet-induced obese mice
• Transient mechanism avoids long-term gut colonization and ecological risks
• Remodels gut microbiota via cross-feeding to enrich native butyrate producers

Planned validation pathway:

• In vitro gastric and bile tolerance testing under simulated canine/feline digestive conditions
• Fecal fermentation assays to confirm SCFA production dynamics and microbial cross-feeding
• 28-day dose-escalation safety study in target animals with hematology, serum chemistry, and fecal shedding monitoring
• 12-week randomized, placebo-controlled efficacy trial in overweight companion animals measuring body weight, body composition, glucose/insulin, and fecal metabolomics

Technology readiness level

The strain has completed preclinical proof-of-concept in three independent diet-induced obesity mouse studies, demonstrating safety and efficacy. The technology is currently at TRL 3–4, with in vitro digestive and microbiome screening and target-animal safety trials planned as the next validation steps. The 12-week efficacy study in companion animals will be required to establish commercial readiness for the pet supplement market.